切换至 "中华医学电子期刊资源库"
高级检索
中华关节外科杂志(电子版)

中华关节外科杂志(电子版) ›› 2020, Vol. 14 ›› Issue (02) : 179 -188. doi: 10.3877/cma.j.issn.1674-134X.2020.02.009

所属专题： 文献；

荟萃研究

唑来膦酸对全髋置换术后假体周围骨密度的影响
刘小垒1, 周义钦2, 钱齐荣2,†()   
  1. 1. 200129　上海开元骨科医院关节外科
    2. 200003　上海长征医院关节外科
  • 收稿日期:2019-12-18 出版日期:2020-04-01
  • 通信作者: 钱齐荣

Effect of zoledronic acid on periprosthetic bone mineral density in osteoporotic patients following total hip replacement

Xiaolei Liu1, Yiqin Zhou2, Qirong Qian2,†()   

  1. 1. Department of joint surgery, Shanghai Kaiyuan Orthopaedic Hospital, Shanghai 200129, China
    2. Department of joint surgery, Shanghai changzheng hospital, Shanghai 200003, China
  • Received:2019-12-18 Published:2020-04-01
  • Corresponding author: Qirong Qian
  • About author:
    Corresponding author: Qian Qirong, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

刘小垒, 周义钦, 钱齐荣. 唑来膦酸对全髋置换术后假体周围骨密度的影响[J]. 中华关节外科杂志(电子版), 2020, 14(02): 179-188.

Xiaolei Liu, Yiqin Zhou, Qirong Qian. Effect of zoledronic acid on periprosthetic bone mineral density in osteoporotic patients following total hip replacement[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2020, 14(02): 179-188.

目的

评价唑来膦酸对骨质疏松患者全髋置换术后假体周围骨密度影响。

方法

检索主要数据库从建库至2019年11月10日唑来膦酸对骨质疏松患者全髋置换术后应用并评价假体周围骨密度结局指标的随机对照试验，筛选合格研究进行分析。偏倚风险评价应用Cochrane评价员手册，质量评价应用Jadad评分法。应用Rev Man 5.3软件对假体周围骨密度指标进行Meta分析。

结果

符合纳入标准的文献共5篇。Meta分析结果显示，术后3个月假体周围骨密度Gruen 2区均数差(MD)＝0.11，95%可信区间(CI)(0.01，0.21)，治疗组与对照组比较，假体周围骨密度Gruen 2区差异有统计学意义(Z ＝2.21，P＝0.03)；Gruen 3区MD＝0.11，95%CI (0.01，0.21)，治疗组与对照组比较，假体周围骨密度Gruen 3区差异有统计学意义(Z＝2.24，P＝0.03)；Gruen 6区MD＝0.12，95%CI(0.04，0.21)，治疗组与对照组比较，假体周围骨密度Gruen 6区差异有统计学意义(Z＝2.76，P＝0.006)。术后6个月假体周围骨密度Gruen 1区MD＝0.05，95%CI(0.01，0.09)，治疗组与对照组比较，假体周围骨密度Gruen 1区差异有统计学意义(Z＝2.20，P＝0.03)；Gruen 2区MD＝0.08，95%CI(0.03，0.14)，治疗组与对照组比较，假体周围骨密度Gruen 2区差异有统计学意义(Z＝3.03，P＝0.002)；Gruen 3区MD＝0.05，95%CI (0.00，0.10)，治疗组与对照组比较，假体周围骨密度Gruen 3区差异有统计学意义(Z＝2.10，P＝0.04)；Gruen 4区MD＝0.10，95%CI(0.04，0.15)，治疗组与对照组比较，假体周围骨密度Gruen 4区差异有统计学意义(Z＝3.46，P＝0.0005)；Gruen 5区MD＝0.08，95% CI(0.03，0.14)，治疗组与对照组比较，假体周围骨密度Gruen 5区差异有统计学意义(Z＝2.87，P＝0.004)。术后12个月假体周围骨密度Gruen 1区MD＝0.09，95%CI(0.05，0.14)，治疗组与对照组比较，假体周围骨密度Gruen 1区差异有统计学意义(Z＝4.22，P<0.0001)；Gruen 2区MD＝0.11，95%CI(0.05，0.16)，治疗组与对照组比较，假体周围骨密度Gruen 2区差异有统计学意义(Z＝3.91，P<0.0001)；Gruen 3区MD＝0.08，95%CI(0.03，0.13)，治疗组与对照组比较，假体周围骨密度Gruen 3区差异有统计学意义(Z＝3.42，P＝0.0006)；Gruen 4区MD＝0.15，95%CI(0.09，0.20)，治疗组与对照组比较，假体周围骨密度Gruen 4区差异有统计学意义(Z＝5.01，P<0.00001)；Gruen 5区MD＝0.10，95%CI(0.05，0.16)，治疗组与对照组比较，假体周围骨密度Gruen 5区差异有统计学意义(Z＝3.77，P＝0.0002)。纳入研究均无重大不良反应发生。

结论

唑来膦酸能有效延缓全髋置换术后假体周围骨密度的降低，增加假体生物学稳定性，且临床应用安全，但需要更多高质量、多中心严格设计的随机对照试验进一步验证。

关键词: 唑来膦酸, 骨质疏松, 关节成形术, 置换, 髋, 骨密度, Meta分析
Objective

To evaluate the effect of zoledronic acid on bone mineral density after total hip arthroplasty in the patients with osteoporosis.

Methods

Main databases from the inception of each database up to 10 November 2019 were electronically searched. Randomized clinical trials (RCTs) of zoledronic acid on bone mineral density after total hip arthroplasty in patients with osteoporosis were included. The Cochrane risk of bias tool was used to assess the risk of bias. The quality of included studies was assessed using the Jadad rating scale. The Cochrane Collaboration’s RevMan5.3 software was used for meta-analysis.

Results

Five studies were included and made a meta-analysis. The meta-analysis results showed that three months after operation, the bone mineral density of Gruen 2 area [mean difference (MD)=0.11, 95% confidence interval (CI) (0.01, 0.21), Z=2.21, P=0.03], Gruen 3 area [MD=0.11, 95% CI (0.01, 0.21), Z=2.24, P=0.03], and Gruen 6 area [MD=0.12, 95% CI (0.04, 0.21), Z=2.76, P=0.006] in the treatment group were significantly higher than those in the control group; six months after operation, the bone mineral density of Gruen 1 area [MD=0.05, 95% CI(0.01, 0.09), Z=2.20, P=0.03], Gruen 2 area [MD=0.08, 95% CI(0.03, 0.14), Z=3.03, P=0.002], Gruen 3 area [MD=0.05, 95% CI (0.00, 0.10), Z=2.10, P=0.04], Gruen 4 area [MD=0.10, 95% CI(0.04, 0.15), Z=3.46, P=0.0005] and Gruen 5 area [MD=0.08, 95% CI (0.03, 0.14), Z=2.87, P=0.004] were significantly higher than those in the control group; 12 months after operation, the bone mineral density of Gruen 1 area [MD=0.09, 95% CI (0.05, 0.14), Z=4.22, P<0.0001], Gruen 2 area [MD=0.11, 95% CI(0.05, 0.16), Z=3.91, P<0.0001], Gruen 3 area [MD=0.08, 95% CI (0.03, 0.13), Z=3.42, P=0.0006], Gruen 4 area [MD=0.15, 95% CI(0.09, 0.20), Z =5.01, P<0.00001] and Gruen 5 area [MD=0.10, 95% CI (0.05, 0.16), Z=3.77, P=0.0002] were significantly higher than those in the control group. No significant adverse reactions occurred in the studies included.

Conclusion

Zoledronic acid can effectively delay the decrease of bone mineral density after total hip arthroplasty, increase the biological stability of the prosthesis, and the clinical application is safe, yet more high quality, multi-center strictly designed RCTs are needed to further verify.

Key words: Zoledronic acid, Osteoporosis, Arthroplasty, replacement, hip, Bone density, Meta-analysis
图1 文献筛选流程图
表1 纳入研究的基本特征
纳入研究 发表时间 例数(治疗组/对照组) 年龄(岁) 诊断 假体情况 治疗组 对照组 不良反应
袁宏等[7] 2014 31(16/15) [70～83，(73.8± 4.21)]/[70～81，(74.1±4.16)] 骨质疏松髋部骨折并行THA 生物型假体 钙尔奇＋阿尔法D3＋唑来膦酸 钙尔奇＋阿尔法D3 治疗组3例出现发热、头痛及流感样症状，对症治疗后好转
王利等[12] 2014 108(54/54) (61±1.2)/(62±1.3) 原发性骨质疏松症接受THA 生物型假体 术后使用唑来膦酸 术后不使用唑来膦酸 未报道
倪小青等[13] 2015 34(17/17) (83.32±2.33)/(82.98±2.99) 原发性骨质疏松症实施THA LINK陶对陶、陶对聚乙烯产品 THA术后加用唑来膦酸 THA术后不加用唑来膦酸 治疗组8例出现发热，乏力、肌肉酸痛等类感冒样症状，对症治疗后好转
Tsan-Wen Huang等[14] 2017 54(27/27) (60.1±11.7)/(59.4±13.3) 骨质疏松症实施THA 生物性假体 使用唑来膦酸 使用生理盐水安慰剂 治疗组3例发热、1例低钙血症
周伟等[15] 2018 32(16/16) (73.3±6.6)/(74.4± 5.7) 绝经后骨质疏松合并髋部骨折行THA 生物性假体 碳酸钙D3片＋骨化三醇胶囊＋唑来膦酸 碳酸钙D3片＋骨化三醇胶囊 治疗组2例出现低热反应
图2 纳入研究的偏倚风险图
图3 纳入研究的偏倚风险概况图
表2 纳入研究的偏倚风险及Jadad评分
纳入研究 发表时间 随机序列的产生 分配隐藏 参与者盲法 评估者盲法 结局数据完整性 选择报告 其他偏倚 Jadad评分
袁宏等[7] 2014 L U H U L U L 3
王利等[12] 2014 L U H U L U L 2
倪小青等[13] 2015 L U H U L U L 2
Tsan-Wen Huang等[14] 2017 L U L L L U L 5
周伟等[15] 2018 L U H L L U L 3
图4 治疗组与对照组术后3个月假体周围骨密度对比森林图
图5 治疗组与对照组术后6个月假体周围骨密度对比森林图
图6 治疗组与对照组术后12个月假体周围骨密度对比森林图
图7 治疗组与对照组术后12个月假体周围骨密度Gruen 1区对比漏斗图
[1]
Solimeo SL, Mccoy K, Reisinger HS, et al. Factors associated with osteoporosis care of men hospitalized for hip fracture: a retrospective cohort study[J/OL]. JBMR Plus, 2019, 3(9): e10198. doi: 10.1002/jbm4.10198.
[2]
Cheung CL, Ang SB, Chadha M, et al. An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study[J]. Osteoporos Sarcopenia, 2018, 4(1): 16-21.
[3]
Godoy Monzón D, Iserson KV, Jauregui J, et al. Total hip arthroplasty for hip fractures: 5-year follow-up of functional outcomes in the oldest independent old and very old patients[J]. Geriatr Orthop Surg Rehabil, 2014, 5(1): 3-8.
[4]
Venesmaa PK, Kroger HP, Miettinen HJ, et al. Monitoring of periprosthetic BMD after uncemented total hip arthroplasty with dual-energy X-ray absorptiometry--a 3-year follow-up study[J]. J Bone Miner Res, 2001, 16(6): 1056-1061.
[5]
Zhou W, Liu Y, Guo X, et al. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis[J]. Osteoporos Int, 2019, 30(8): 1581-1589.
[6]
Fu GT, Lin LJ, Sheng PY, et al. Efficiency of zoledronic acid in inhibiting accelerated periprosthetic bone loss after cementless total hip arthroplasty in osteoporotic patients：a prospective, cohort study[J]. Orthop Surg, 2019, 11(4): 653-663.
[7]
袁宏，陆琳松，钟惠琴，等．唑来膦酸对骨质疏松患者全髋关节置换术后假体周围骨密度的影响[J/CD]．中华关节外科杂志(电子版)，2014，8(3): 278-285.
[8]
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration's tool for assessing risk of bias in randomised trials[J/OL]. BMJ, 2011, 343: d5928. doi: 10.1136/bmj.d5928.
[9]
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? [J]. Control Clin Trials, 1996, 17(1): 1-12.
[10]
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses[J]. BMJ, 2003, 327(7414): 557-560.
[11]
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis[J]. Stat Med, 2002, 21(11): 1539-1558.
[12]
王利，哈巴西·卡肯，殷剑，等．唑来膦酸钠治疗全髋关节置换术后早期假体周围骨密度变化[J/CD]．中华临床医师杂志(电子版)，2014，8(15): 2898-2900.
[13]
倪小青，卢全中，潘风雨，等．唑来膦酸预防高龄骨质疏松骨折全髋关节置换术后骨丢失的临床研究[J]．临床和实验医学杂志，2015，14(5): 391-393.
[14]
Huang TW, Wang CJ, Shih HN, et al. Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial[J/OL]. BMC Musculoskelet Disord, 2017, 18(1): 209. doi: 10.1186/s12891-017-1577-2.
[15]
周伟，郭晓斌，刘禹，等．唑来膦酸对绝经后骨质疏松症患者假体周围骨密度的影响[J]．中国骨质疏松杂志，2018，24(4): 488-494.
[16]
Furnes O, Lie SA, Espehaug B, et al. Hip disease and the prognosis of total hip replacements.A review of 53，698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987－99[J]. J Bone Joint Surg Br, 2001, 83(4): 579-586.
[17]
Muratore M, Quarta E, Quarta L, et al. Ibandronate and cementless total hip arthroplasty：densitometric measurement of periprosthetic bone mass and new therapeutic approach to the prevention of aseptic loosening[J]. Clin Cases Miner Bone Metab, 2012, 9(1): 50-55.
[18]
Lee YK, Kim TY, Ha YC, et al. To withhold or to implement bisphosphonate after cementless hip arthroplasty：a dilemma in elderly hip fracture patients[J/OL]. J Orthop Surg Res, 2019, 14(1): 66. doi: 10.1186/s13018-019-1104-2.
[19]
Aro E, Moritz N, Mattila K, et al. A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: a randomized placebo-controlled trial of women undergoing total hip arthroplasty[J]. J Biomech, 2018, 75: 35-45.
[20]
吴立忠，李炜明．双膦酸盐类药物对全髋置换术后假体周围骨密度影响的研究进展[J]．福建医药杂志，2015，37(6): 152-153，178.
[1] 周钰菡, 肖欢, 唐毅, 杨春江, 周娟, 朱丽容, 徐娟, 牟芳婷. 超声对儿童髋关节暂时性滑膜炎的诊断价值[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 795-800.
[2] 林文, 王雨萱, 许嘉悦, 王矜群, 王睿娜, 何董源, 樊沛. 人工关节置换登记系统的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 834-841.
[3] 闫文, 谢兴文, 顾玉彪, 雷宁波, 马成, 于文霞, 高亚雄, 张磊. 微小RNA与全膝关节置换术后深静脉血栓的研究进展[J]. 中华关节外科杂志(电子版), 2023, 17(06): 842-846.
[4] 贺敬龙, 尚宏喜, 郝敏, 谢伟, 高明宏, 孙炜, 刘安庆. 重度类风湿关节炎患者行多关节置换术的临床手术疗效[J]. 中华关节外科杂志(电子版), 2023, 17(06): 860-864.
[5] 孟繁宇, 周新社, 赵志, 裴立家, 刘犇. 侧位直接前方入路髋关节置换治疗偏瘫肢体股骨颈骨折[J]. 中华关节外科杂志(电子版), 2023, 17(06): 865-870.
[6] 王宏宇. 固定与活动平台假体在全膝关节置换术中的应用价值[J]. 中华关节外科杂志(电子版), 2023, 17(06): 871-876.
[7] 李善武, 叶永杰, 王兵, 王子呓, 银毅, 孙官军, 张大刚. 胫骨高位截骨与单髁置换的早期疗效比较[J]. 中华关节外科杂志(电子版), 2023, 17(06): 882-888.
[8] 李辉, 吴奇, 张子琦, 张晗, 王仿, 许鹏. 日间全膝关节置换术早期疗效及标准化流程探索[J]. 中华关节外科杂志(电子版), 2023, 17(06): 889-892.
[9] 中华医学会骨科学分会关节外科学组, 广东省医学会骨质疏松和骨矿盐疾病分会, 广东省佛山市顺德区第三人民医院. 中国髋部脆性骨折术后抗骨质疏松药物临床干预指南(2023年版)[J]. 中华关节外科杂志(电子版), 2023, 17(06): 751-764.
[10] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[11] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[12] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[13] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[14] 中华医学会骨科分会关节学组. 中国髋、膝关节置换日间手术围手术期管理专家共识[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 321-332.
[15] 付庆鹏, 邓晓强, 高伟, 姜福民, 范永峰, 吴海贺, 齐岩松, 包呼日查, 徐永胜. 新型股骨测量定位器在全膝关节置换术中的临床应用[J]. 中华临床医师杂志(电子版), 2023, 17(9): 980-987.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号